Sotorasib Patent Expiration
Sotorasib is Used for treating adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. It was first introduced by Amgen Inc
Sotorasib Patents
Given below is the list of patents protecting Sotorasib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lumakras | US11426404 | Dosing of KRAS inhibitor for treatment of cancers | Sep 15, 2040 | Amgen Inc |
| Lumakras | US11236091 | Solid state forms | May 20, 2040 | Amgen Inc |
| Lumakras | US11827635 | Solid state forms | May 20, 2040 | Amgen Inc |
| Lumakras | US12280056 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | Nov 18, 2039 | Amgen Inc |
| Lumakras | US10519146 | KRAS G12C inhibitors and methods of using the same | May 21, 2038 | Amgen Inc |
Sotorasib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List